AU2002363859B2 - Substituted 2-pyrrolidine-2-yl-1H-indole derivatives for the treatment of migraine - Google Patents

Substituted 2-pyrrolidine-2-yl-1H-indole derivatives for the treatment of migraine Download PDF

Info

Publication number
AU2002363859B2
AU2002363859B2 AU2002363859A AU2002363859A AU2002363859B2 AU 2002363859 B2 AU2002363859 B2 AU 2002363859B2 AU 2002363859 A AU2002363859 A AU 2002363859A AU 2002363859 A AU2002363859 A AU 2002363859A AU 2002363859 B2 AU2002363859 B2 AU 2002363859B2
Authority
AU
Australia
Prior art keywords
alkyl
aryl
denotes
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002363859A
Other languages
English (en)
Other versions
AU2002363859A1 (en
Inventor
Helmut Buschmann
Hagen-Heinrich Hennies
Bernd Sundermann
Corinna Sundermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2002363859A1 publication Critical patent/AU2002363859A1/en
Application granted granted Critical
Publication of AU2002363859B2 publication Critical patent/AU2002363859B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2002363859A 2001-12-06 2002-12-02 Substituted 2-pyrrolidine-2-yl-1H-indole derivatives for the treatment of migraine Ceased AU2002363859B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10159922.6 2001-12-06
DE10159922A DE10159922A1 (de) 2001-12-06 2001-12-06 Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
PCT/EP2002/013613 WO2003048156A1 (de) 2001-12-06 2002-12-02 Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne

Publications (2)

Publication Number Publication Date
AU2002363859A1 AU2002363859A1 (en) 2003-06-17
AU2002363859B2 true AU2002363859B2 (en) 2008-09-18

Family

ID=7708242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002363859A Ceased AU2002363859B2 (en) 2001-12-06 2002-12-02 Substituted 2-pyrrolidine-2-yl-1H-indole derivatives for the treatment of migraine

Country Status (18)

Country Link
US (1) US7271192B2 (da)
EP (1) EP1451177B1 (da)
JP (1) JP4663982B2 (da)
AR (1) AR037707A1 (da)
AT (1) ATE357441T1 (da)
AU (1) AU2002363859B2 (da)
CA (1) CA2469346C (da)
CY (1) CY1106576T1 (da)
DE (2) DE10159922A1 (da)
DK (1) DK1451177T3 (da)
ES (1) ES2284973T3 (da)
HU (1) HUP0402283A3 (da)
MX (1) MXPA04005139A (da)
PE (1) PE20030748A1 (da)
PL (1) PL371270A1 (da)
PT (1) PT1451177E (da)
SI (1) SI1451177T1 (da)
WO (1) WO2003048156A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385702T3 (es) 2005-06-07 2012-07-30 Kyowa Hakko Kirin Co., Ltd. Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CN112010841A (zh) * 2020-08-20 2020-12-01 上海体育学院 一种基于吲哚骨架的吡咯烷衍生物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3506683A (en) * 1963-10-07 1970-04-14 Upjohn Co 3-(2-pyrrolidinylidene)-3h-indoles
ES2143992T3 (es) * 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
GB9523999D0 (en) * 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
KR20030060904A (ko) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Foster et al., Chemical Communications, 1968, 1440-1441 *
Furstner et al., J. Org. Chem., 1994, 59, 5215-5229 *

Also Published As

Publication number Publication date
ES2284973T3 (es) 2007-11-16
EP1451177A1 (de) 2004-09-01
CY1106576T1 (el) 2012-01-25
DK1451177T3 (da) 2007-07-02
PT1451177E (pt) 2007-04-30
JP2005511694A (ja) 2005-04-28
WO2003048156A1 (de) 2003-06-12
PL371270A1 (en) 2005-06-13
PE20030748A1 (es) 2003-09-05
US20050014815A1 (en) 2005-01-20
AU2002363859A1 (en) 2003-06-17
CA2469346C (en) 2010-10-19
US7271192B2 (en) 2007-09-18
DE10159922A1 (de) 2003-06-26
CA2469346A1 (en) 2003-06-12
HUP0402283A2 (hu) 2005-02-28
ATE357441T1 (de) 2007-04-15
JP4663982B2 (ja) 2011-04-06
HUP0402283A3 (en) 2009-07-28
SI1451177T1 (sl) 2007-08-31
EP1451177B1 (de) 2007-03-21
MXPA04005139A (es) 2004-08-11
AR037707A1 (es) 2004-12-01
DE50209798D1 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
KR100817373B1 (ko) 화학적 화합물
EP2804868B1 (en) Pyran-spirocyclic piperidine amides as modulators of ion channels
EP1948654B1 (en) 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
AU2019244400A1 (en) Factor XIIa inhibitors
JP7191826B2 (ja) 三環式ｒｈｏキナーゼ阻害剤
WO2018050686A1 (en) Spiro bicyclic inhibitors of menin-mll interaction
JP4866730B2 (ja) 置換された３−ピロリジン−インドール−誘導体
AU2017326487B2 (en) Spiro bicyclic inhibitors of menin-MLL interaction
RU2528406C2 (ru) Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
MX2013006951A (es) Compuestos antivirales.
MX2013004150A (es) Conpuestos antivirales.
MXPA03004717A (es) Compuestos especificos para el receptor a1, a2 y a3 de adenosina y usos de los mismos.
BRPI0616944B1 (pt) compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem
TW201022246A (en) Melanocortin receptor agonists
AU2013243898A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW201811759A (zh) 二芳基甲基雜環
KR0179073B1 (ko) 5-ht1 작용물질로서의 인돌 유도체
JP2021534106A (ja) Ｐａｄ４阻害剤としての置換チエノピロール
TW201817713A (zh) 血腦屏障－穿透劑多巴胺－β－羥化酶抑制劑
AU2002363859B2 (en) Substituted 2-pyrrolidine-2-yl-1H-indole derivatives for the treatment of migraine
RU2425830C2 (ru) Новые производные винилогенных кислот
JPH08245624A (ja) ジオキソピロロ−ピロール誘導体
TW201932470A (zh) 具有抗ｒｓｖ活性之吡唑并嘧啶
JP2005511694A6 (ja) 置換された２−ピロリジン−２−イル−１ｈ−インドール誘導体
MXPA02003802A (es) Derivado de n-acilpirrolidin-2-ilalquilbenzamidina como inhibidores de factor xa.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired